Characteristics of t-AML/MDS patients, genetic alterations, and response to induction chemotherapy in 95 patients undergoing and not undergoing aSCT (11 patients with unclear transplantation status excluded)
| . | Allogeneic transplantation (n = 45) . | No allogeneic transplantation (n = 50) . |
|---|---|---|
| Sex | ||
| Male | 50% | 64% |
| Age at t-AML/MDS diagnosis | ||
| Median (range) | 41 (20-68) | 55 (18-74) |
| Time from HL treatment to diagnosis of t-AML/MDS | ||
| Median (range), months | 30 (11-101) | 28 (7-124) |
| Cytogenetics/molecular genetic alterations reported | 39 (87%) | 20 (40%) |
| Normal karyotype | 6 | 0 |
| Alterations of chromosomes 5/7 | 8 | 0 |
| MLL rearrangement | 13 | 5 |
| Complex karyotype | 3 | 11 |
| Other genetic alterations | 9 | 4 |
| Response to induction therapy reported | 35 (78%) | N/A |
| CR | 23 | |
| Blast reduction, but no CR | 3 | |
| Refractory/relapsed | 7 | |
| No induction therapy | 2 |
| . | Allogeneic transplantation (n = 45) . | No allogeneic transplantation (n = 50) . |
|---|---|---|
| Sex | ||
| Male | 50% | 64% |
| Age at t-AML/MDS diagnosis | ||
| Median (range) | 41 (20-68) | 55 (18-74) |
| Time from HL treatment to diagnosis of t-AML/MDS | ||
| Median (range), months | 30 (11-101) | 28 (7-124) |
| Cytogenetics/molecular genetic alterations reported | 39 (87%) | 20 (40%) |
| Normal karyotype | 6 | 0 |
| Alterations of chromosomes 5/7 | 8 | 0 |
| MLL rearrangement | 13 | 5 |
| Complex karyotype | 3 | 11 |
| Other genetic alterations | 9 | 4 |
| Response to induction therapy reported | 35 (78%) | N/A |
| CR | 23 | |
| Blast reduction, but no CR | 3 | |
| Refractory/relapsed | 7 | |
| No induction therapy | 2 |
N/A, not available.